Follow-The-Filings

Security · featured owners

CTMX Cytomx Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.3%
  • $2M
  • 1 add

CTMX (Cytomx Therapeutics Inc.) is held in 1 featured 13F book as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (0.31%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.3% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel add 0.31%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 0.31% Add +90.6% 438,407 $2M history

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 15 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
8-K 1.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
424B5 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Aug 3, 2026 Filing Doc
4 Period Jul 24, 2026 Filing Doc
4 Period Jun 17, 2026 · 7 forms Filing Doc
4 Period Jun 15, 2026 Filing Doc
4 Period Mar 17, 2026 · 4 forms Filing Doc
4 Period Feb 2, 2026 · 5 forms Filing Doc
4 Period Nov 6, 2025 Filing Doc
4 Period Oct 20, 2025 Filing Doc
4 Period Sep 26, 2025 · 4 forms Filing Doc

Updated 5 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $101.21M $138.1M $76.2M
Net income -$0.569M $31.87M -$17.37M
Net margin * -0.6% 23.1% -22.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $182.94M $107.3M $143.92M
Total non-current assets * $18.86M $13.23M $7.64M
Total assets $201.79M $120.53M $151.57M
Total current liabilities $155.91M $85.77M $46.62M
Total non-current liabilities * $93.33M $35.22M $5.94M
Total equity -$47.45M -$0.456M $99.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$56.04M -$86.23M -$75.59M
Cash from investing -$150.67M $99.7M -$59.74M
Cash from financing $30.23M $7.52M $110.45M
Net change in cash * -$176.48M $20.99M -$24.88M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders